CN111093680A - 治疗变应性气道疾病(aad)/哮喘的方法 - Google Patents

治疗变应性气道疾病(aad)/哮喘的方法 Download PDF

Info

Publication number
CN111093680A
CN111093680A CN201880059290.3A CN201880059290A CN111093680A CN 111093680 A CN111093680 A CN 111093680A CN 201880059290 A CN201880059290 A CN 201880059290A CN 111093680 A CN111093680 A CN 111093680A
Authority
CN
China
Prior art keywords
mca
msc
asthma
mscs
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880059290.3A
Other languages
English (en)
Chinese (zh)
Inventor
C·塞缪尔
S·罗伊斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cynata Therapeutics Ltd
Original Assignee
Cynata Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017903758A external-priority patent/AU2017903758A0/en
Application filed by Cynata Therapeutics Ltd filed Critical Cynata Therapeutics Ltd
Publication of CN111093680A publication Critical patent/CN111093680A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0668—Mesenchymal stem cells from other natural sources
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • C12N5/0692—Stem cells; Progenitor cells; Precursor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/12—Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/03—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from non-embryonic pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2511/00—Cells for large scale production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Pulmonology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201880059290.3A 2017-09-15 2018-08-31 治疗变应性气道疾病(aad)/哮喘的方法 Pending CN111093680A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2017903758 2017-09-15
AU2017903758A AU2017903758A0 (en) 2017-09-15 Method
PCT/AU2018/050937 WO2019051536A1 (en) 2017-09-15 2018-08-31 METHOD OF TREATING ALLERGIC RESPIRATORY TRACT DISEASE (DAA) / ASTHMA

Publications (1)

Publication Number Publication Date
CN111093680A true CN111093680A (zh) 2020-05-01

Family

ID=65722228

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880059290.3A Pending CN111093680A (zh) 2017-09-15 2018-08-31 治疗变应性气道疾病(aad)/哮喘的方法

Country Status (14)

Country Link
US (1) US11471493B2 (enExample)
EP (1) EP3681519B1 (enExample)
JP (1) JP2020533373A (enExample)
KR (1) KR20200053501A (enExample)
CN (1) CN111093680A (enExample)
AR (1) AR112802A1 (enExample)
AU (1) AU2018333272B2 (enExample)
BR (1) BR112020004856A2 (enExample)
CA (1) CA3074470C (enExample)
ES (1) ES2996339T3 (enExample)
MX (1) MX2020002760A (enExample)
SG (1) SG11202001909TA (enExample)
TW (1) TWI806896B (enExample)
WO (1) WO2019051536A1 (enExample)

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1953765A (zh) * 2004-05-12 2007-04-25 东亚制药株式会社 含有fgf2作为有效成分的治疗或预防哮喘和慢性阻塞性肺病的药剂
WO2013134378A1 (en) * 2012-03-07 2013-09-12 Janssen Biotech, Inc. Defined media for expansion and maintenance of pluripotent stem cells
WO2013151725A1 (en) * 2012-04-05 2013-10-10 The Regents Of The University Of California Regenerative sera cells and mesenchymal stem cells
CN103403150A (zh) * 2010-12-17 2013-11-20 人类起源公司 利用羊膜来源贴壁细胞治疗与免疫相关的疾病和紊乱
CA2877223A1 (en) * 2012-08-06 2014-02-13 Brainstorm Cell Therapeutics Ltd. Methods of generating mesenchymal stem cells which secrete neurotrophic factors
CN104471059A (zh) * 2012-07-12 2015-03-25 爱姆斯坦生物技术公司 人胚胎干细胞衍生的间充质样干细胞、方法及其应用
CN104704122A (zh) * 2012-04-20 2015-06-10 艾珀特玛治疗公司 产热的miRNA调节剂
CN105377274A (zh) * 2012-12-12 2016-03-02 麦瑟布莱斯特公司 治疗或预防呼吸病症的方法
WO2017156580A1 (en) * 2016-03-16 2017-09-21 Cynata Therapeutics Limited Colony forming medium and use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX366900B (es) 2013-03-13 2019-07-30 Wisconsin Alumni Res Found Métodos y materiales para diferenciación hematoendotelial de células germinales pluripotentes humanas bajo condiciones definidas.
JP2018501241A (ja) * 2014-12-19 2018-01-18 セル・アイディアズ・ピーティーワイ・リミテッド 改良された細胞療法
JP2019523293A (ja) * 2016-08-04 2019-08-22 ハドソン インスティテュート オブ メディカル リサーチ 処置の方法
JP2020523400A (ja) 2017-06-16 2020-08-06 サイナータ セラピューティクス リミテッド 免疫療法の副作用を治療するための方法

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1953765A (zh) * 2004-05-12 2007-04-25 东亚制药株式会社 含有fgf2作为有效成分的治疗或预防哮喘和慢性阻塞性肺病的药剂
CN103403150A (zh) * 2010-12-17 2013-11-20 人类起源公司 利用羊膜来源贴壁细胞治疗与免疫相关的疾病和紊乱
WO2013134378A1 (en) * 2012-03-07 2013-09-12 Janssen Biotech, Inc. Defined media for expansion and maintenance of pluripotent stem cells
WO2013151725A1 (en) * 2012-04-05 2013-10-10 The Regents Of The University Of California Regenerative sera cells and mesenchymal stem cells
CN104704122A (zh) * 2012-04-20 2015-06-10 艾珀特玛治疗公司 产热的miRNA调节剂
CN104471059A (zh) * 2012-07-12 2015-03-25 爱姆斯坦生物技术公司 人胚胎干细胞衍生的间充质样干细胞、方法及其应用
CA2877223A1 (en) * 2012-08-06 2014-02-13 Brainstorm Cell Therapeutics Ltd. Methods of generating mesenchymal stem cells which secrete neurotrophic factors
CN105377274A (zh) * 2012-12-12 2016-03-02 麦瑟布莱斯特公司 治疗或预防呼吸病症的方法
WO2017156580A1 (en) * 2016-03-16 2017-09-21 Cynata Therapeutics Limited Colony forming medium and use thereof

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
KOCH JM等: "Mesenchymoangioblast-derived mesenchymal stromal cells inhibit cell damage, tissue damage and improve peripheral blood flow following hindlimb ischemic injury in mice", 《CYTOTHERAPY》 *
QU YING等: "Exosomes derived from miR-181-5p-modified adipose-derived mesenchymal stem cells prevent liver fibrosis via autophagy activation", 《J CELL MOL MED》 *
ROYCE SG等: "Intranasal administration of mesenchymoangioblast-derived mesenchymal stem cells abrogates airway fibrosis and airway hyperresponsiveness associated with chronic allergic airways disease", 《FASEB J》 *
ROYCE SG等: "iPSC- and mesenchymoangioblast-derived mesenchymal stem cells provide greater protection against experimental chronic allergic airways disease compared with a clinically used corticosteroid", 《FASEB J》 *
ROYCE SG等: "Mesenchymal stem cells and serelaxin synergistically abrogate established airway fibrosis in an experimental model of chronic allergic airways disease", 《STEM CELL RES》 *
TANG GN等: "MicroRNAs Involved in Asthma After Mesenchymal Stem Cells Treatment", 《STEM CELLS DEV》 *
VODYANIK MA 等: "A mesoderm-derived precursor for mesenchymal stem and endothelial cells", 《CELL STEM CELL》 *
任妮娜 等: "人脐带间充质干细胞移植对支气管哮喘小鼠气道炎症的作用及其机制", 《中华医学杂志》 *
王敏: "MicroRNAs调控人脂肪源性干细胞成骨分化及ODN影响其调控的研究", 《中国博士学位论文全文数据库》 *
颛孙永勋 等: "间充质干细胞对去除CD4~+CD25~+调节性T细胞哮喘小鼠气道炎症的影响", 《中国组织工程研究》 *

Also Published As

Publication number Publication date
KR20200053501A (ko) 2020-05-18
RU2020111190A (ru) 2021-10-15
JP2020533373A (ja) 2020-11-19
AU2018333272B2 (en) 2022-12-08
CA3074470C (en) 2024-01-16
RU2020111190A3 (enExample) 2022-03-30
EP3681519B1 (en) 2024-10-30
BR112020004856A2 (pt) 2020-09-15
CA3074470A1 (en) 2019-03-21
TW201919666A (zh) 2019-06-01
MX2020002760A (es) 2020-07-20
TWI806896B (zh) 2023-07-01
US11471493B2 (en) 2022-10-18
AR112802A1 (es) 2019-12-11
AU2018333272A1 (en) 2020-03-05
EP3681519C0 (en) 2024-10-30
ES2996339T3 (en) 2025-02-12
EP3681519A4 (en) 2021-04-28
EP3681519A1 (en) 2020-07-22
SG11202001909TA (en) 2020-04-29
WO2019051536A1 (en) 2019-03-21
US20200276243A1 (en) 2020-09-03

Similar Documents

Publication Publication Date Title
JP2023093589A (ja) 幹細胞の免疫制御作用を調節する方法
US20110044958A1 (en) Activated mesenchymal stem cells for the prevention and repair of inflammatory states
Guo et al. Mesenchymal stem cells reprogram host macrophages to attenuate obliterative bronchiolitis in murine orthotopic tracheal transplantation
US20250340940A1 (en) Treatment of Atopic Dermatitis Using Mesenchymal Stem Cells and Immune Modulation
Yan et al. Intra‐articular injection of human synovial membrane‐derived mesenchymal stem cells in murine collagen‐induced arthritis: assessment of immunomodulatory capacity in vivo
Li et al. Critical role of alternative M2 skewing in miR-155 deletion-mediated protection of colitis
Ikhapoh et al. Sry-type HMG box 18 contributes to the differentiation of bone marrow-derived mesenchymal stem cells to endothelial cells
CN111093680A (zh) 治疗变应性气道疾病(aad)/哮喘的方法
RU2790031C2 (ru) Способ лечения аллергического заболевания дыхательных путей (AAD)/астмы
HK40024451A (en) Method for treating allergic airways disease (aad)/ asthma
HK40024451B (en) Method for treating allergic airways disease (aad)/ asthma
Li et al. Preconditioning mesenchymal stromal cells with flagellin enhances the anti-inflammatory ability of their secretome against lipopolysaccharide-induced acute lung injury
US20250388970A1 (en) Treatment of Atopic Dermatitis Using Mesenchymal Stem Cells and Immune Modulation
EP3873503B1 (en) Treatment of cachexia using fibroblast cells and products thereof
CN113069472B (zh) 肝脏前体细胞、其制备方法以及在抑郁症治疗中的用途
US20160158289A1 (en) Materials and methods for using adipose stem cells to treat lung injury and disease
WO2022241090A9 (en) Methods and compositions for treating liver disease
HK40116423A (en) Treatment of cachexia using fibroblast cells and products thereof
Lynch Regulation of Inflammation and Skeletal Muscle Repair by Mohawk and Eosinophils
HK40039711A (en) Composition and method for muscle repair and regeneration
Zhao et al. Research Article Infusion of Bone Marrow Mesenchymal Stem Cells Attenuates Experimental Severe Acute Pancreatitis in Rats

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination